| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 19 | 2025 | 223 | 3.760 |
Why?
|
| Tumor Suppressor Proteins | 28 | 2015 | 484 | 3.130 |
Why?
|
| Kidney Neoplasms | 21 | 2025 | 421 | 3.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 11 | 2023 | 167 | 3.050 |
Why?
|
| Leiomyoma | 20 | 2024 | 71 | 3.000 |
Why?
|
| Uterine Neoplasms | 19 | 2024 | 100 | 2.780 |
Why?
|
| Epigenesis, Genetic | 21 | 2024 | 757 | 2.300 |
Why?
|
| Peroxisomes | 5 | 2018 | 42 | 2.280 |
Why?
|
| Autophagy | 13 | 2020 | 417 | 2.050 |
Why?
|
| Endocrine Disruptors | 11 | 2024 | 55 | 1.900 |
Why?
|
| TOR Serine-Threonine Kinases | 19 | 2015 | 429 | 1.800 |
Why?
|
| DNA-Binding Proteins | 8 | 2025 | 1939 | 1.740 |
Why?
|
| Signal Transduction | 34 | 2019 | 4686 | 1.710 |
Why?
|
| Reactive Oxygen Species | 8 | 2018 | 521 | 1.670 |
Why?
|
| Carcinoma, Medullary | 7 | 2025 | 17 | 1.620 |
Why?
|
| Lysine | 5 | 2020 | 167 | 1.260 |
Why?
|
| Estrogens | 9 | 2014 | 434 | 1.210 |
Why?
|
| Prenatal Exposure Delayed Effects | 5 | 2019 | 237 | 1.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 6 | 2016 | 94 | 1.150 |
Why?
|
| Actins | 2 | 2020 | 321 | 1.100 |
Why?
|
| Animals | 85 | 2026 | 33912 | 1.070 |
Why?
|
| Histones | 11 | 2021 | 541 | 1.050 |
Why?
|
| Rats | 37 | 2023 | 3370 | 1.040 |
Why?
|
| Autism Spectrum Disorder | 10 | 2025 | 450 | 1.000 |
Why?
|
| Protein Kinases | 6 | 2010 | 312 | 0.970 |
Why?
|
| Multiprotein Complexes | 7 | 2015 | 195 | 0.950 |
Why?
|
| Placenta | 11 | 2025 | 504 | 0.950 |
Why?
|
| SMARCB1 Protein | 5 | 2025 | 42 | 0.940 |
Why?
|
| Environmental Exposure | 12 | 2026 | 298 | 0.920 |
Why?
|
| Repressor Proteins | 10 | 2005 | 760 | 0.880 |
Why?
|
| Disease Susceptibility | 5 | 2019 | 274 | 0.870 |
Why?
|
| Epigenomics | 8 | 2025 | 181 | 0.860 |
Why?
|
| Endometrial Neoplasms | 5 | 2010 | 110 | 0.860 |
Why?
|
| Cell Cycle Proteins | 5 | 2017 | 710 | 0.850 |
Why?
|
| Cytoplasm | 4 | 2011 | 249 | 0.840 |
Why?
|
| Microtubules | 6 | 2021 | 133 | 0.840 |
Why?
|
| Receptors, Estrogen | 4 | 2013 | 732 | 0.830 |
Why?
|
| Diethylstilbestrol | 4 | 2010 | 39 | 0.810 |
Why?
|
| DNA Helicases | 1 | 2025 | 239 | 0.790 |
Why?
|
| Cytoskeleton | 4 | 2021 | 166 | 0.790 |
Why?
|
| Tubulin | 3 | 2021 | 76 | 0.770 |
Why?
|
| Methylation | 9 | 2021 | 199 | 0.770 |
Why?
|
| Environmental Pollutants | 5 | 2026 | 78 | 0.740 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 4 | 2011 | 57 | 0.730 |
Why?
|
| Cell Transformation, Neoplastic | 5 | 2018 | 587 | 0.710 |
Why?
|
| Gene Expression Regulation, Neoplastic | 15 | 2025 | 2026 | 0.690 |
Why?
|
| Gene Expression Regulation, Developmental | 5 | 2016 | 950 | 0.680 |
Why?
|
| Proteostasis | 2 | 2019 | 37 | 0.660 |
Why?
|
| Humans | 107 | 2025 | 131163 | 0.660 |
Why?
|
| Phosphorylation | 17 | 2016 | 1571 | 0.650 |
Why?
|
| Mutation, Missense | 1 | 2025 | 919 | 0.650 |
Why?
|
| Transcription Factors | 6 | 2022 | 2406 | 0.650 |
Why?
|
| Estrogens, Non-Steroidal | 5 | 2017 | 13 | 0.640 |
Why?
|
| Cardiomyopathies | 1 | 2025 | 514 | 0.620 |
Why?
|
| Transcriptome | 4 | 2026 | 1103 | 0.620 |
Why?
|
| Proto-Oncogene Proteins c-akt | 7 | 2010 | 480 | 0.620 |
Why?
|
| GTP-Binding Proteins | 1 | 2020 | 156 | 0.620 |
Why?
|
| Myometrium | 7 | 2024 | 47 | 0.610 |
Why?
|
| Polycystic Kidney Diseases | 3 | 2006 | 31 | 0.610 |
Why?
|
| Membrane Proteins | 6 | 2020 | 1590 | 0.600 |
Why?
|
| Proteomics | 2 | 2023 | 615 | 0.590 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2020 | 248 | 0.580 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2016 | 335 | 0.570 |
Why?
|
| Immunohistochemistry | 7 | 2016 | 1591 | 0.560 |
Why?
|
| Mice, Inbred C57BL | 6 | 2024 | 4738 | 0.560 |
Why?
|
| Insulin Receptor Substrate Proteins | 4 | 2019 | 72 | 0.560 |
Why?
|
| 14-3-3 Proteins | 4 | 2016 | 56 | 0.550 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 2 | 2015 | 318 | 0.540 |
Why?
|
| Histone Code | 3 | 2019 | 46 | 0.540 |
Why?
|
| Macaca mulatta | 2 | 2022 | 504 | 0.530 |
Why?
|
| Adiposity | 2 | 2020 | 209 | 0.530 |
Why?
|
| DNA Methylation | 12 | 2026 | 1077 | 0.530 |
Why?
|
| Microbiota | 1 | 2023 | 438 | 0.530 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3748 | 0.520 |
Why?
|
| Hydrocortisone | 1 | 2018 | 215 | 0.520 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2014 | 35 | 0.510 |
Why?
|
| Female | 69 | 2026 | 70963 | 0.510 |
Why?
|
| Gene-Environment Interaction | 3 | 2020 | 127 | 0.510 |
Why?
|
| MCF-7 Cells | 8 | 2017 | 209 | 0.500 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2009 | 252 | 0.500 |
Why?
|
| Mice | 29 | 2026 | 18301 | 0.500 |
Why?
|
| Chromatin Assembly and Disassembly | 2 | 2021 | 121 | 0.500 |
Why?
|
| Cell Line | 10 | 2020 | 2552 | 0.490 |
Why?
|
| Prostatic Neoplasms | 3 | 2016 | 1419 | 0.490 |
Why?
|
| AMP-Activated Protein Kinases | 5 | 2013 | 170 | 0.480 |
Why?
|
| Social Behavior | 1 | 2018 | 214 | 0.480 |
Why?
|
| Homeostasis | 2 | 2018 | 712 | 0.480 |
Why?
|
| Organelles | 1 | 2016 | 20 | 0.470 |
Why?
|
| Endometrial Hyperplasia | 3 | 2010 | 21 | 0.460 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 81 | 0.460 |
Why?
|
| Methyltransferases | 1 | 2016 | 78 | 0.460 |
Why?
|
| Blotting, Western | 9 | 2016 | 1013 | 0.450 |
Why?
|
| Emotions | 1 | 2018 | 350 | 0.450 |
Why?
|
| Genes, Tumor Suppressor | 7 | 2006 | 200 | 0.450 |
Why?
|
| Behavior, Animal | 1 | 2018 | 480 | 0.450 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 6 | 2015 | 179 | 0.450 |
Why?
|
| Adaptation, Psychological | 1 | 2018 | 431 | 0.440 |
Why?
|
| Anemia, Sickle Cell | 2 | 2018 | 334 | 0.430 |
Why?
|
| beta Catenin | 2 | 2014 | 197 | 0.430 |
Why?
|
| Liver Neoplasms | 2 | 2024 | 1373 | 0.430 |
Why?
|
| Aurora Kinase A | 1 | 2014 | 37 | 0.420 |
Why?
|
| Pregnancy | 24 | 2025 | 7512 | 0.410 |
Why?
|
| Autistic Disorder | 4 | 2022 | 398 | 0.410 |
Why?
|
| Protein Processing, Post-Translational | 5 | 2021 | 359 | 0.410 |
Why?
|
| Disease Models, Animal | 11 | 2025 | 4697 | 0.410 |
Why?
|
| Adenylate Kinase | 2 | 2010 | 12 | 0.400 |
Why?
|
| Hormones | 3 | 2016 | 162 | 0.390 |
Why?
|
| Phenols | 5 | 2026 | 73 | 0.390 |
Why?
|
| Cell Membrane | 5 | 2016 | 450 | 0.390 |
Why?
|
| Benzhydryl Compounds | 5 | 2026 | 79 | 0.380 |
Why?
|
| Genomic Instability | 4 | 2025 | 245 | 0.380 |
Why?
|
| Antibodies, Monoclonal | 2 | 2016 | 981 | 0.380 |
Why?
|
| Neoplasm Proteins | 2 | 2016 | 680 | 0.370 |
Why?
|
| Biomarkers | 8 | 2025 | 3385 | 0.370 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2013 | 242 | 0.370 |
Why?
|
| Mitochondria | 1 | 2018 | 785 | 0.360 |
Why?
|
| TRPP Cation Channels | 2 | 2010 | 6 | 0.360 |
Why?
|
| Genistein | 1 | 2012 | 40 | 0.360 |
Why?
|
| Mitosis | 4 | 2025 | 191 | 0.340 |
Why?
|
| Genitalia, Male | 1 | 2011 | 33 | 0.340 |
Why?
|
| Multienzyme Complexes | 2 | 2008 | 76 | 0.340 |
Why?
|
| Biomarkers, Tumor | 5 | 2025 | 1586 | 0.340 |
Why?
|
| Cells | 1 | 2011 | 20 | 0.340 |
Why?
|
| Protein Binding | 6 | 2021 | 1652 | 0.330 |
Why?
|
| Trans-Activators | 3 | 2024 | 697 | 0.330 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2016 | 1205 | 0.330 |
Why?
|
| Genitalia, Female | 1 | 2011 | 44 | 0.330 |
Why?
|
| HEK293 Cells | 5 | 2016 | 801 | 0.320 |
Why?
|
| Tumor Cells, Cultured | 10 | 2020 | 975 | 0.320 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2010 | 588 | 0.310 |
Why?
|
| Male | 32 | 2025 | 64957 | 0.310 |
Why?
|
| Cyclonic Storms | 2 | 2021 | 82 | 0.310 |
Why?
|
| Disasters | 2 | 2021 | 101 | 0.300 |
Why?
|
| Carcinogens | 3 | 2008 | 127 | 0.300 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 36 | 0.290 |
Why?
|
| Maternal Exposure | 3 | 2019 | 150 | 0.290 |
Why?
|
| Uterus | 3 | 2010 | 541 | 0.280 |
Why?
|
| Kidney | 5 | 2023 | 1282 | 0.280 |
Why?
|
| Trialkyltin Compounds | 2 | 2026 | 8 | 0.280 |
Why?
|
| Polychlorinated Biphenyls | 2 | 2021 | 14 | 0.280 |
Why?
|
| Mice, Knockout | 10 | 2019 | 3819 | 0.270 |
Why?
|
| Carcinoma | 1 | 2010 | 291 | 0.270 |
Why?
|
| Sirolimus | 5 | 2010 | 230 | 0.260 |
Why?
|
| Extracellular Matrix | 3 | 2024 | 232 | 0.260 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2008 | 3436 | 0.260 |
Why?
|
| Quinoxalines | 1 | 2007 | 39 | 0.250 |
Why?
|
| Activin Receptors, Type I | 1 | 2007 | 34 | 0.250 |
Why?
|
| Proteins | 5 | 2010 | 1006 | 0.250 |
Why?
|
| Selective Estrogen Receptor Modulators | 2 | 2004 | 51 | 0.250 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2007 | 111 | 0.240 |
Why?
|
| Trichloroethylene | 1 | 2006 | 2 | 0.240 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 3 | 2014 | 90 | 0.240 |
Why?
|
| Solvents | 1 | 2006 | 39 | 0.240 |
Why?
|
| Hydrogen Peroxide | 2 | 2018 | 116 | 0.240 |
Why?
|
| Imidazoles | 1 | 2007 | 219 | 0.230 |
Why?
|
| Centrosome | 1 | 2025 | 28 | 0.230 |
Why?
|
| Haploinsufficiency | 2 | 2025 | 266 | 0.230 |
Why?
|
| Cysteine | 1 | 2006 | 137 | 0.230 |
Why?
|
| Ipilimumab | 1 | 2025 | 64 | 0.230 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2025 | 31 | 0.220 |
Why?
|
| Cellular Reprogramming | 3 | 2016 | 129 | 0.220 |
Why?
|
| CA-125 Antigen | 1 | 2025 | 14 | 0.220 |
Why?
|
| Rats, Mutant Strains | 6 | 2010 | 14 | 0.220 |
Why?
|
| Chromatin | 4 | 2025 | 499 | 0.220 |
Why?
|
| Reproduction | 2 | 2008 | 210 | 0.220 |
Why?
|
| High-Throughput Screening Assays | 2 | 2017 | 119 | 0.220 |
Why?
|
| Penetrance | 1 | 2005 | 107 | 0.220 |
Why?
|
| Estradiol | 5 | 2010 | 460 | 0.210 |
Why?
|
| Vitamins | 1 | 2025 | 111 | 0.210 |
Why?
|
| Isochromosomes | 1 | 2023 | 17 | 0.200 |
Why?
|
| Liver | 4 | 2024 | 1796 | 0.200 |
Why?
|
| Cells, Cultured | 6 | 2017 | 2885 | 0.200 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2003 | 73 | 0.200 |
Why?
|
| Anxiety | 2 | 2021 | 1014 | 0.200 |
Why?
|
| Biological Assay | 2 | 2016 | 105 | 0.200 |
Why?
|
| Patient Selection | 2 | 2018 | 729 | 0.200 |
Why?
|
| Vascular Neoplasms | 1 | 2003 | 31 | 0.200 |
Why?
|
| Sickle Cell Trait | 1 | 2023 | 10 | 0.200 |
Why?
|
| Receptors, Progesterone | 2 | 2007 | 677 | 0.190 |
Why?
|
| Genes, cdc | 1 | 2003 | 23 | 0.190 |
Why?
|
| Tuberous Sclerosis | 4 | 2010 | 147 | 0.190 |
Why?
|
| Environmental Health | 1 | 2023 | 22 | 0.190 |
Why?
|
| Adult | 18 | 2025 | 31282 | 0.190 |
Why?
|
| Carcinogenesis | 4 | 2023 | 336 | 0.190 |
Why?
|
| Thiophenes | 1 | 2003 | 69 | 0.190 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2002 | 46 | 0.190 |
Why?
|
| Docosahexaenoic Acids | 1 | 2003 | 67 | 0.190 |
Why?
|
| Thiazolidinediones | 1 | 2003 | 81 | 0.180 |
Why?
|
| Mothers | 2 | 2016 | 388 | 0.180 |
Why?
|
| Serine | 2 | 2015 | 161 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 57 | 0.180 |
Why?
|
| DNA Replication | 2 | 2023 | 355 | 0.180 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 972 | 0.180 |
Why?
|
| Prostate | 2 | 2015 | 404 | 0.180 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2003 | 251 | 0.170 |
Why?
|
| Lymphangioleiomyomatosis | 3 | 2010 | 21 | 0.170 |
Why?
|
| Dietary Supplements | 1 | 2025 | 448 | 0.170 |
Why?
|
| Microscopy, Fluorescence | 3 | 2015 | 303 | 0.170 |
Why?
|
| Piperidines | 1 | 2003 | 223 | 0.170 |
Why?
|
| Tamoxifen | 1 | 2003 | 348 | 0.170 |
Why?
|
| Chromosome Aberrations | 2 | 2023 | 573 | 0.170 |
Why?
|
| Polycomb Repressive Complex 2 | 2 | 2012 | 33 | 0.170 |
Why?
|
| RNA Interference | 2 | 2015 | 491 | 0.170 |
Why?
|
| Deer | 1 | 2021 | 15 | 0.170 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 1295 | 0.170 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2012 | 69 | 0.160 |
Why?
|
| Risk Factors | 10 | 2018 | 11074 | 0.160 |
Why?
|
| Floods | 1 | 2021 | 21 | 0.160 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 664 | 0.160 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 258 | 0.160 |
Why?
|
| Catalytic Domain | 1 | 2021 | 161 | 0.160 |
Why?
|
| Sequence Deletion | 1 | 2003 | 516 | 0.160 |
Why?
|
| Autophagy-Related Proteins | 1 | 2020 | 37 | 0.160 |
Why?
|
| Hypoxia | 2 | 2023 | 247 | 0.160 |
Why?
|
| Disaster Planning | 1 | 2021 | 68 | 0.160 |
Why?
|
| Reading | 1 | 2021 | 76 | 0.160 |
Why?
|
| Models, Biological | 4 | 2016 | 1371 | 0.160 |
Why?
|
| Loss of Heterozygosity | 4 | 2009 | 123 | 0.160 |
Why?
|
| Gene Knockout Techniques | 1 | 2020 | 133 | 0.160 |
Why?
|
| Organotin Compounds | 1 | 2020 | 6 | 0.160 |
Why?
|
| Phenotype | 3 | 2025 | 4497 | 0.160 |
Why?
|
| Rats, Sprague-Dawley | 4 | 2016 | 1105 | 0.150 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 288 | 0.150 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2002 | 597 | 0.150 |
Why?
|
| Antibodies | 2 | 2016 | 322 | 0.150 |
Why?
|
| HeLa Cells | 5 | 2017 | 686 | 0.150 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2019 | 7 | 0.150 |
Why?
|
| Antineoplastic Agents | 3 | 2019 | 1826 | 0.150 |
Why?
|
| Cell Division | 5 | 2003 | 718 | 0.150 |
Why?
|
| Health Promotion | 1 | 2023 | 422 | 0.150 |
Why?
|
| Halogenated Diphenyl Ethers | 2 | 2021 | 12 | 0.150 |
Why?
|
| Gene Deletion | 2 | 2018 | 767 | 0.150 |
Why?
|
| Breast Neoplasms | 3 | 2014 | 2602 | 0.140 |
Why?
|
| Child Development | 2 | 2024 | 266 | 0.140 |
Why?
|
| Depression, Postpartum | 1 | 2019 | 52 | 0.140 |
Why?
|
| Rhabdoid Tumor | 1 | 2019 | 46 | 0.140 |
Why?
|
| Pregnancy Complications | 2 | 2021 | 567 | 0.140 |
Why?
|
| Down-Regulation | 1 | 2020 | 645 | 0.140 |
Why?
|
| Hyperoxia | 1 | 2020 | 136 | 0.140 |
Why?
|
| Eligibility Determination | 1 | 2018 | 38 | 0.140 |
Why?
|
| Genomic Imprinting | 1 | 2019 | 121 | 0.140 |
Why?
|
| Carcinogens, Environmental | 2 | 2015 | 12 | 0.140 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2019 | 128 | 0.140 |
Why?
|
| Osmotic Pressure | 1 | 2018 | 23 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 1336 | 0.140 |
Why?
|
| Hypersensitivity | 1 | 2021 | 227 | 0.140 |
Why?
|
| Immunoblotting | 2 | 2010 | 292 | 0.140 |
Why?
|
| Stress, Psychological | 2 | 2021 | 536 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2018 | 89 | 0.130 |
Why?
|
| Mad2 Proteins | 1 | 2017 | 7 | 0.130 |
Why?
|
| Estrogen Receptor beta | 2 | 2017 | 87 | 0.130 |
Why?
|
| Hepatocyte Nuclear Factor 1-beta | 1 | 2017 | 27 | 0.130 |
Why?
|
| Cohort Studies | 6 | 2025 | 5063 | 0.130 |
Why?
|
| Breast Feeding | 1 | 2019 | 240 | 0.130 |
Why?
|
| Embryonic Development | 1 | 2019 | 200 | 0.130 |
Why?
|
| PDZ Domains | 1 | 2016 | 10 | 0.130 |
Why?
|
| Mutation | 5 | 2021 | 6099 | 0.130 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 1363 | 0.120 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2016 | 34 | 0.120 |
Why?
|
| Cell Compartmentation | 1 | 2016 | 38 | 0.120 |
Why?
|
| Rats, Inbred Strains | 2 | 2007 | 181 | 0.120 |
Why?
|
| Apoptosis | 4 | 2020 | 1827 | 0.120 |
Why?
|
| Organ Specificity | 2 | 2011 | 394 | 0.120 |
Why?
|
| Siblings | 3 | 2024 | 201 | 0.120 |
Why?
|
| Fetal Proteins | 1 | 2016 | 11 | 0.120 |
Why?
|
| National Institute of Child Health and Human Development (U.S.) | 1 | 2016 | 8 | 0.120 |
Why?
|
| Cytokinesis | 1 | 2016 | 23 | 0.120 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2016 | 21 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 3 | 2010 | 1447 | 0.120 |
Why?
|
| Protein Array Analysis | 2 | 2009 | 104 | 0.120 |
Why?
|
| Peroxisome-Targeting Signal 1 Receptor | 1 | 2015 | 2 | 0.120 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 223 | 0.120 |
Why?
|
| Sequestosome-1 Protein | 1 | 2015 | 15 | 0.110 |
Why?
|
| Phagosomes | 1 | 2015 | 38 | 0.110 |
Why?
|
| Growth Substances | 2 | 2006 | 99 | 0.110 |
Why?
|
| Hep G2 Cells | 1 | 2015 | 83 | 0.110 |
Why?
|
| Epithelial Cells | 2 | 2014 | 905 | 0.110 |
Why?
|
| Chromosome Mapping | 1 | 2018 | 1046 | 0.110 |
Why?
|
| Oxidative Stress | 2 | 2010 | 791 | 0.110 |
Why?
|
| Growth and Development | 1 | 2015 | 19 | 0.110 |
Why?
|
| Mammaglobin B | 1 | 2015 | 1 | 0.110 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2016 | 263 | 0.110 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 305 | 0.110 |
Why?
|
| Health | 1 | 2015 | 35 | 0.110 |
Why?
|
| Maternal Behavior | 1 | 2015 | 66 | 0.110 |
Why?
|
| Longitudinal Studies | 4 | 2022 | 1490 | 0.110 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2005 | 82 | 0.110 |
Why?
|
| Disease Progression | 3 | 2025 | 2200 | 0.110 |
Why?
|
| Brain | 4 | 2022 | 3175 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 174 | 0.110 |
Why?
|
| Anticarcinogenic Agents | 1 | 2015 | 47 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 2 | 2017 | 431 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 722 | 0.110 |
Why?
|
| Mammals | 1 | 2016 | 253 | 0.110 |
Why?
|
| Neoplasms | 3 | 2017 | 3016 | 0.110 |
Why?
|
| Endoplasmic Reticulum | 1 | 2015 | 208 | 0.110 |
Why?
|
| Cell Proliferation | 5 | 2020 | 2465 | 0.100 |
Why?
|
| Gene Expression Profiling | 4 | 2025 | 1801 | 0.100 |
Why?
|
| Dichlorodiphenyl Dichloroethylene | 1 | 2014 | 14 | 0.100 |
Why?
|
| ral GTP-Binding Proteins | 1 | 2014 | 4 | 0.100 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2014 | 28 | 0.100 |
Why?
|
| DNA Repair | 2 | 2023 | 571 | 0.100 |
Why?
|
| DNA Damage | 2 | 2023 | 511 | 0.100 |
Why?
|
| Carotenoids | 1 | 2015 | 79 | 0.100 |
Why?
|
| Cilia | 1 | 2014 | 74 | 0.100 |
Why?
|
| Pesticides | 1 | 2014 | 26 | 0.100 |
Why?
|
| Disease | 1 | 2015 | 121 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2018 | 1129 | 0.100 |
Why?
|
| Fetal Blood | 2 | 2025 | 176 | 0.100 |
Why?
|
| Veterans | 1 | 2025 | 1763 | 0.100 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2015 | 619 | 0.100 |
Why?
|
| Risk Assessment | 3 | 2017 | 3711 | 0.100 |
Why?
|
| Proteome | 1 | 2015 | 285 | 0.100 |
Why?
|
| Rats, Long-Evans | 2 | 2003 | 95 | 0.100 |
Why?
|
| Autoantibodies | 1 | 2016 | 451 | 0.100 |
Why?
|
| Epithelium | 1 | 2014 | 335 | 0.100 |
Why?
|
| Middle Aged | 8 | 2025 | 28601 | 0.090 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 155 | 0.090 |
Why?
|
| Memory | 1 | 2015 | 314 | 0.090 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2014 | 106 | 0.090 |
Why?
|
| Obesity | 5 | 2021 | 2426 | 0.090 |
Why?
|
| Transforming Growth Factor beta | 2 | 2023 | 451 | 0.090 |
Why?
|
| Genome, Human | 3 | 2016 | 1321 | 0.090 |
Why?
|
| Stem Cells | 2 | 2015 | 702 | 0.090 |
Why?
|
| Infant | 6 | 2025 | 13352 | 0.090 |
Why?
|
| Caenorhabditis elegans | 1 | 2014 | 251 | 0.090 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 402 | 0.090 |
Why?
|
| Child, Preschool | 7 | 2025 | 15110 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 631 | 0.090 |
Why?
|
| Cellular Senescence | 1 | 2014 | 217 | 0.090 |
Why?
|
| RNA, Messenger | 3 | 2009 | 2550 | 0.090 |
Why?
|
| Pregnancy Trimester, Third | 2 | 2024 | 122 | 0.090 |
Why?
|
| Prospective Studies | 4 | 2025 | 6459 | 0.090 |
Why?
|
| Neurons | 1 | 2021 | 1979 | 0.090 |
Why?
|
| Ligands | 2 | 2003 | 481 | 0.090 |
Why?
|
| Tissue Distribution | 1 | 2012 | 358 | 0.080 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2011 | 25 | 0.080 |
Why?
|
| Health Personnel | 1 | 2016 | 541 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2011 | 53 | 0.080 |
Why?
|
| Gene Silencing | 3 | 2015 | 229 | 0.080 |
Why?
|
| Transcriptional Activation | 2 | 2003 | 419 | 0.080 |
Why?
|
| Genotype | 2 | 2010 | 2595 | 0.080 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 192 | 0.080 |
Why?
|
| Microscopy, Confocal | 2 | 2015 | 335 | 0.080 |
Why?
|
| DNA | 3 | 2022 | 1399 | 0.080 |
Why?
|
| Calcium | 1 | 2015 | 1010 | 0.080 |
Why?
|
| Cell Death | 1 | 2011 | 224 | 0.080 |
Why?
|
| Depression | 1 | 2019 | 1320 | 0.080 |
Why?
|
| Polycystic Kidney, Autosomal Dominant | 1 | 2010 | 11 | 0.080 |
Why?
|
| Immunoprecipitation | 1 | 2010 | 189 | 0.080 |
Why?
|
| Time Factors | 4 | 2014 | 6196 | 0.080 |
Why?
|
| Cadherins | 2 | 2019 | 182 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2016 | 294 | 0.070 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2009 | 41 | 0.070 |
Why?
|
| Thymidine Kinase | 1 | 2009 | 90 | 0.070 |
Why?
|
| Up-Regulation | 3 | 2015 | 825 | 0.070 |
Why?
|
| Infant, Newborn | 5 | 2022 | 8635 | 0.070 |
Why?
|
| Microsatellite Repeats | 1 | 2009 | 204 | 0.070 |
Why?
|
| Postpartum Period | 2 | 2021 | 245 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 410 | 0.070 |
Why?
|
| Subcellular Fractions | 1 | 2008 | 89 | 0.070 |
Why?
|
| COS Cells | 2 | 2021 | 253 | 0.070 |
Why?
|
| Genital Diseases, Female | 1 | 2008 | 31 | 0.070 |
Why?
|
| Chromones | 1 | 2008 | 26 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2020 | 188 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2020 | 700 | 0.070 |
Why?
|
| Cytosol | 1 | 2008 | 135 | 0.070 |
Why?
|
| Androstadienes | 1 | 2008 | 50 | 0.070 |
Why?
|
| Fibroblasts | 3 | 2018 | 849 | 0.070 |
Why?
|
| Peutz-Jeghers Syndrome | 1 | 2008 | 28 | 0.070 |
Why?
|
| Morpholines | 1 | 2008 | 66 | 0.070 |
Why?
|
| Amino Acid Sequence | 3 | 2016 | 2395 | 0.070 |
Why?
|
| Benzoates | 1 | 2007 | 24 | 0.070 |
Why?
|
| Animals, Newborn | 3 | 2020 | 1021 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2007 | 56 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2011 | 420 | 0.060 |
Why?
|
| California | 2 | 2018 | 127 | 0.060 |
Why?
|
| Genome-Wide Association Study | 3 | 2020 | 1833 | 0.060 |
Why?
|
| Calbindins | 1 | 2007 | 18 | 0.060 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2007 | 22 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2007 | 131 | 0.060 |
Why?
|
| Ribosomal Protein S6 Kinases | 2 | 2008 | 48 | 0.060 |
Why?
|
| Glutamates | 1 | 2007 | 53 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2007 | 33 | 0.060 |
Why?
|
| Endometrium | 1 | 2010 | 292 | 0.060 |
Why?
|
| Kidney Tubules | 1 | 2007 | 76 | 0.060 |
Why?
|
| Surveys and Questionnaires | 3 | 2025 | 4066 | 0.060 |
Why?
|
| Benzimidazoles | 1 | 2007 | 161 | 0.060 |
Why?
|
| Cell Survival | 1 | 2009 | 826 | 0.060 |
Why?
|
| Carcinogenicity Tests | 1 | 2006 | 17 | 0.060 |
Why?
|
| Kidney Cortex | 1 | 2006 | 19 | 0.060 |
Why?
|
| Endothelial Growth Factors | 2 | 2003 | 37 | 0.060 |
Why?
|
| Adenoviridae | 1 | 2009 | 579 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factors | 2 | 2003 | 47 | 0.060 |
Why?
|
| Lymphokines | 2 | 2003 | 62 | 0.060 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2008 | 324 | 0.060 |
Why?
|
| Overweight | 2 | 2021 | 387 | 0.060 |
Why?
|
| Prognosis | 3 | 2020 | 4886 | 0.060 |
Why?
|
| Risk | 2 | 2019 | 726 | 0.060 |
Why?
|
| Cell Nucleus | 1 | 2008 | 556 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2009 | 1545 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2013 | 992 | 0.060 |
Why?
|
| Base Sequence | 2 | 2015 | 2730 | 0.060 |
Why?
|
| Chromosome Segregation | 1 | 2025 | 68 | 0.060 |
Why?
|
| Adenoma | 1 | 2007 | 144 | 0.060 |
Why?
|
| ras Proteins | 1 | 2006 | 140 | 0.060 |
Why?
|
| Enzyme Inhibitors | 1 | 2008 | 573 | 0.060 |
Why?
|
| Microscopy | 2 | 2017 | 118 | 0.060 |
Why?
|
| Pregnancy Outcome | 1 | 2008 | 623 | 0.060 |
Why?
|
| Acetylation | 2 | 2015 | 190 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2010 | 2326 | 0.050 |
Why?
|
| Germ-Line Mutation | 2 | 2007 | 373 | 0.050 |
Why?
|
| Serum Response Factor | 1 | 2024 | 30 | 0.050 |
Why?
|
| Prevalence | 2 | 2016 | 2701 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 2 | 2003 | 325 | 0.050 |
Why?
|
| DNA Mutational Analysis | 1 | 2006 | 775 | 0.050 |
Why?
|
| Fibronectins | 1 | 2024 | 99 | 0.050 |
Why?
|
| Diabetes, Gestational | 2 | 2016 | 112 | 0.050 |
Why?
|
| Genetic Therapy | 1 | 2009 | 713 | 0.050 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2004 | 69 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 378 | 0.050 |
Why?
|
| Streptozocin | 1 | 2003 | 25 | 0.050 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2003 | 23 | 0.050 |
Why?
|
| Cytogenetics | 1 | 2023 | 13 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2008 | 663 | 0.050 |
Why?
|
| Embryo, Mammalian | 2 | 2017 | 403 | 0.050 |
Why?
|
| Centromere | 1 | 2023 | 67 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2012 | 2323 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2003 | 68 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2003 | 83 | 0.050 |
Why?
|
| Prostaglandin D2 | 1 | 2003 | 4 | 0.050 |
Why?
|
| Chromans | 1 | 2003 | 8 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2020 | 889 | 0.050 |
Why?
|
| Cyclopentanes | 1 | 2023 | 21 | 0.050 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2003 | 27 | 0.050 |
Why?
|
| Precancerous Conditions | 1 | 2006 | 281 | 0.050 |
Why?
|
| Carboplatin | 1 | 2023 | 79 | 0.050 |
Why?
|
| Aged | 4 | 2025 | 21025 | 0.050 |
Why?
|
| United States | 4 | 2025 | 12072 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 633 | 0.050 |
Why?
|
| Receptors, Oxytocin | 1 | 2003 | 20 | 0.050 |
Why?
|
| Connexin 43 | 1 | 2003 | 34 | 0.050 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 63 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2003 | 234 | 0.050 |
Why?
|
| 3T3 Cells | 1 | 2002 | 117 | 0.050 |
Why?
|
| Progestins | 1 | 2002 | 39 | 0.050 |
Why?
|
| Estrous Cycle | 1 | 2002 | 40 | 0.050 |
Why?
|
| CpG Islands | 2 | 2015 | 337 | 0.050 |
Why?
|
| Ultrasonic Therapy | 1 | 2002 | 26 | 0.050 |
Why?
|
| HMGA2 Protein | 1 | 2002 | 12 | 0.050 |
Why?
|
| Karyotyping | 1 | 2003 | 308 | 0.050 |
Why?
|
| Leiomyosarcoma | 1 | 2002 | 22 | 0.050 |
Why?
|
| Antibody Specificity | 1 | 2002 | 164 | 0.050 |
Why?
|
| Thiazoles | 1 | 2003 | 113 | 0.050 |
Why?
|
| Metabolome | 1 | 2025 | 326 | 0.050 |
Why?
|
| Tandem Mass Spectrometry | 2 | 2015 | 289 | 0.050 |
Why?
|
| Substrate Specificity | 1 | 2002 | 287 | 0.050 |
Why?
|
| Genes, Regulator | 1 | 2022 | 44 | 0.040 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2002 | 71 | 0.040 |
Why?
|
| Ribosomal Proteins | 1 | 2002 | 70 | 0.040 |
Why?
|
| Progesterone | 1 | 2004 | 439 | 0.040 |
Why?
|
| DNA Primers | 1 | 2003 | 599 | 0.040 |
Why?
|
| Hydroquinones | 2 | 2017 | 12 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2002 | 308 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2003 | 423 | 0.040 |
Why?
|
| Energy Metabolism | 1 | 2007 | 804 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2019 | 3359 | 0.040 |
Why?
|
| Cell Movement | 2 | 2002 | 876 | 0.040 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 116 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2006 | 477 | 0.040 |
Why?
|
| Reference Values | 1 | 2003 | 676 | 0.040 |
Why?
|
| Incidence | 1 | 2009 | 3360 | 0.040 |
Why?
|
| Qualitative Research | 1 | 2025 | 730 | 0.040 |
Why?
|
| Sociological Factors | 1 | 2021 | 9 | 0.040 |
Why?
|
| Heterozygote | 1 | 2003 | 737 | 0.040 |
Why?
|
| Industry | 1 | 2021 | 29 | 0.040 |
Why?
|
| Genes, Reporter | 1 | 2002 | 341 | 0.040 |
Why?
|
| Glutathione | 1 | 2002 | 200 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 1 | 2002 | 716 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2015 | 3464 | 0.040 |
Why?
|
| Goals | 1 | 2021 | 126 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 1011 | 0.040 |
Why?
|
| Enzyme Activation | 3 | 2011 | 576 | 0.040 |
Why?
|
| Dysbiosis | 1 | 2021 | 145 | 0.040 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2020 | 38 | 0.040 |
Why?
|
| Nucleotidyltransferases | 1 | 2020 | 47 | 0.040 |
Why?
|
| Metabolomics | 1 | 2024 | 501 | 0.040 |
Why?
|
| Toxicity Tests | 1 | 2020 | 34 | 0.040 |
Why?
|
| Binding Sites | 1 | 2002 | 1133 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2009 | 183 | 0.040 |
Why?
|
| Retrospective Studies | 1 | 2018 | 17753 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2023 | 446 | 0.040 |
Why?
|
| North Carolina | 1 | 2019 | 48 | 0.040 |
Why?
|
| Bottle Feeding | 1 | 2019 | 39 | 0.040 |
Why?
|
| Oogenesis | 1 | 2019 | 50 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2019 | 52 | 0.040 |
Why?
|
| Mice, 129 Strain | 1 | 2019 | 96 | 0.040 |
Why?
|
| Unfolded Protein Response | 1 | 2019 | 66 | 0.040 |
Why?
|
| Myocardium | 1 | 2003 | 852 | 0.040 |
Why?
|
| Young Adult | 3 | 2021 | 10103 | 0.040 |
Why?
|
| Wnt Proteins | 1 | 2019 | 191 | 0.030 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2018 | 6 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2019 | 116 | 0.030 |
Why?
|
| National Institute of Environmental Health Sciences (U.S.) | 1 | 2018 | 3 | 0.030 |
Why?
|
| Umbilical Cord | 1 | 2018 | 56 | 0.030 |
Why?
|
| Chorionic Villi | 1 | 2017 | 20 | 0.030 |
Why?
|
| Photography | 1 | 2018 | 79 | 0.030 |
Why?
|
| Kidney Tubules, Proximal | 1 | 2018 | 74 | 0.030 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2019 | 156 | 0.030 |
Why?
|
| Organ Size | 1 | 2018 | 407 | 0.030 |
Why?
|
| Child | 4 | 2022 | 26341 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1618 | 0.030 |
Why?
|
| Chromosomal Instability | 1 | 2017 | 59 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 151 | 0.030 |
Why?
|
| Oocytes | 1 | 2019 | 283 | 0.030 |
Why?
|
| Aneuploidy | 1 | 2017 | 138 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2016 | 64 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 1267 | 0.030 |
Why?
|
| Cytokines | 1 | 2022 | 1339 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2017 | 315 | 0.030 |
Why?
|
| Cell Count | 1 | 2016 | 212 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2016 | 112 | 0.030 |
Why?
|
| Sampling Studies | 1 | 2016 | 76 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2019 | 749 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2016 | 299 | 0.030 |
Why?
|
| Lung | 2 | 2020 | 1535 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2016 | 195 | 0.030 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2019 | 830 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 713 | 0.030 |
Why?
|
| Stromal Interaction Molecule 1 | 1 | 2015 | 8 | 0.030 |
Why?
|
| Trypsin | 1 | 2015 | 68 | 0.030 |
Why?
|
| Embryology | 1 | 2015 | 1 | 0.030 |
Why?
|
| Steroids | 1 | 2016 | 170 | 0.030 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 1272 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2019 | 1410 | 0.030 |
Why?
|
| Genome | 1 | 2018 | 451 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 585 | 0.030 |
Why?
|
| Boston | 1 | 2015 | 117 | 0.030 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 325 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2017 | 594 | 0.030 |
Why?
|
| Adolescent | 3 | 2021 | 20987 | 0.030 |
Why?
|
| Biological Transport | 1 | 2015 | 329 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1029 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2015 | 623 | 0.030 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2015 | 80 | 0.030 |
Why?
|
| Research Design | 1 | 2018 | 716 | 0.030 |
Why?
|
| Chromatography, Gas | 1 | 2014 | 20 | 0.030 |
Why?
|
| Neural Stem Cells | 1 | 2015 | 133 | 0.030 |
Why?
|
| Ras Homolog Enriched in Brain Protein | 1 | 2014 | 5 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 2015 | 110 | 0.030 |
Why?
|
| Telomere | 1 | 2015 | 219 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 330 | 0.030 |
Why?
|
| Spermine | 1 | 2013 | 7 | 0.030 |
Why?
|
| Nitric Oxide Donors | 1 | 2013 | 18 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2018 | 1240 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2015 | 286 | 0.020 |
Why?
|
| Sulfites | 1 | 2013 | 26 | 0.020 |
Why?
|
| Oxygen | 1 | 2016 | 548 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2014 | 318 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 552 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 674 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2015 | 448 | 0.020 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2018 | 629 | 0.020 |
Why?
|
| Texas | 1 | 2021 | 3686 | 0.020 |
Why?
|
| Genomics | 1 | 2020 | 1621 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 526 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2014 | 765 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2011 | 62 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 1207 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2011 | 80 | 0.020 |
Why?
|
| Algorithms | 1 | 2017 | 1680 | 0.020 |
Why?
|
| Retreatment | 1 | 2010 | 85 | 0.020 |
Why?
|
| Everolimus | 1 | 2010 | 50 | 0.020 |
Why?
|
| Nitric Oxide | 1 | 2013 | 471 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2013 | 407 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 1634 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2011 | 288 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 235 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 386 | 0.020 |
Why?
|
| Cisplatin | 1 | 2011 | 274 | 0.020 |
Why?
|
| Anoikis | 1 | 2009 | 8 | 0.020 |
Why?
|
| Aging | 1 | 2016 | 1242 | 0.020 |
Why?
|
| Ganciclovir | 1 | 2009 | 101 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2009 | 121 | 0.020 |
Why?
|
| Herpesvirus 1, Human | 1 | 2009 | 41 | 0.020 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 73 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2015 | 2904 | 0.020 |
Why?
|
| Ovariectomy | 1 | 2009 | 152 | 0.020 |
Why?
|
| Benzamides | 1 | 2009 | 127 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 2825 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2008 | 40 | 0.020 |
Why?
|
| Homozygote | 1 | 2010 | 533 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2008 | 99 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2010 | 711 | 0.020 |
Why?
|
| Gene Expression | 2 | 2003 | 1481 | 0.020 |
Why?
|
| RNA, Neoplasm | 1 | 2008 | 125 | 0.020 |
Why?
|
| Hypertension | 1 | 2016 | 1356 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2007 | 55 | 0.020 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2007 | 39 | 0.020 |
Why?
|
| Hyperplasia | 1 | 2007 | 191 | 0.020 |
Why?
|
| Recurrence | 1 | 2010 | 1489 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 713 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2007 | 729 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 993 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2009 | 807 | 0.010 |
Why?
|
| Cyclooxygenase 1 | 1 | 2003 | 21 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2003 | 65 | 0.010 |
Why?
|
| Ribosomal Protein S6 | 1 | 2002 | 14 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 121 | 0.010 |
Why?
|
| Oxytocin | 1 | 2003 | 68 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2002 | 16 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 211 | 0.010 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2002 | 27 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2002 | 106 | 0.010 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2002 | 40 | 0.010 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2002 | 48 | 0.010 |
Why?
|
| Dogs | 1 | 2002 | 613 | 0.010 |
Why?
|
| Transfection | 1 | 2002 | 962 | 0.010 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 344 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 6797 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2002 | 605 | 0.010 |
Why?
|